U.S. patent number 3,651,806 [Application Number 04/869,136] was granted by the patent office on 1972-03-28 for method and apparatus for administering digitalizing medications.
Invention is credited to Philip I. Hirshberg.
| United States Patent |
3,651,806 |
| Hirshberg |
March 28, 1972 |
| **Please see images for:
( Certificate of Correction ) ** |
METHOD AND APPARATUS FOR ADMINISTERING DIGITALIZING MEDICATIONS
Abstract
A method and apparatus for infusing digitalizing medication to a
patient at a controlled rate. The apparatus including first
detection means for recognizing an electrical event originating in
the muscle of the heart, electrical stimulation means responsive to
the electrical event for stimulating the heart with an electrical
stimulating signal, second detection means for detecting an
electrical signal indicative of the response of the heart to the
electrical stimulating signal, and infusion means including means
responsive to said last mentioned electrical signal to control the
amount of medication administered to the patient.
|
Inventors: |
Hirshberg; Philip I. (Needham,
MA) |
| Family
ID: |
25352987 |
| Appl.
No.: |
04/869,136 |
| Filed: |
October 24, 1969 |
| Current U.S.
Class: |
604/503; 604/66;
128/DIG.13 |
| Current CPC
Class: |
A61B
5/352 (20210101); A61M 5/1723 (20130101); Y10S
128/13 (20130101) |
| Current International
Class: |
A61B
5/0452 (20060101); A61B 5/0456 (20060101); A61M
5/172 (20060101); A61M 5/168 (20060101); A61m
005/00 () |
| Field of
Search: |
;128/213-218,DIG.1,2,2.05,2.06,DIG.13 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
Lown et al., Proceed. Society Exper. Biol. & Med., Vol. 126,
1967, pp 698-701.
|
Primary Examiner: Truluck; Dalton L.
Claims
What is claimed:
1. In the method of administering digitalizing medications to a
patient which includes automatically administering a digitalizing
medication to a patient, the steps of applying an electrical
stimulus to the heart of the patient, detecting the response to the
stimulus to then determine the toxicity of the patient, and then
adjusting the amount of digitalizing medication being automatically
administered to the patient in accordance with the determined
toxicity of the patient in order to maintain a predetermined
percentage of toxic dosage of digitalizing medication in the
patient.
2. The method according to claim 1 in which the digitalizing
medication is administered to the patient by infusion.
3. The method according to claim 2 in which the stimulus is applied
between an interval of heart contraction in order to elicit a
response indicative of the toxicity of the patient.
4. The method according to claim 3 in which the stimulus is applied
during the latter half of the interval between heart contractions,
the portion of time in the R -- R interval that the stimulus is
applied, between contractions, which elicits a response indicates
the toxicity of the patient.
5. The method according to claim 4 in which the presence of a
response to the stimulus is converted to an error signal for
controlling the rate of medication being provided to a patient
using infusion means.
6. In a system for infusing digitalizing medications to a patient
comprising means for infusing digitalizing medication into a
patient, first means for detecting an electrical event originating
in the muscle of the heart, second means responsive to the
electrical event for providing an electrical stimulus to stimulate
the heart a predetermined time interval after the onset of said
electrical event, and third means for detecting the response to
said electrical stimulus from said heart and set the amount of
medication administered to the patient by said means for
infusing.
7. In a system according to claim 6 wherein said first means
detects the presence of an R wave produced by the muscle of the
heart, wherein said second means produces an RVR electrical
stimulus a predetermined time after the R wave is detected, wherein
said third means detects the RVR response to the RVR electrical
stimulus and also determines the position of the RVR electrical
stimulus with respect to the normal R -- R interval produced by the
heart of the patient so as to determine the toxicity of the patient
and set the rate of infusion.
8. In a system according to claim 6 wherein said third means
includes means which provides an indication of the toxicity of the
patient which is then used to maintain the amount of medication
being administered to the patient at a predetermined desired
rate.
9. In a system according to claim 8 including means for only
permitting the response to be used to control the infusion of
medication during a predetermined interval of the R -- R wave
interval.
10. In a system according to claim 6 including means for varying
the time at which the heart is stimulated.
11. In the method of automatically administering digitalizing
medication to a patient which comprises the steps of applying an
electrical stimulatory signal to the heart of a patient, detecting
if a response occurs to said stimulus, and then controlling the
automatic administration of the digitalizing medication after the
toxicity of the patient has been determined, depending upon where
in the R -- R interval the electrical stimulus is applied and a
response is detected.
Description
Digitalis preparations are among the most commonly utilized
pharmaceutical agents (i.e., Acetyl Strophanthidin, Ouabin and
Digoxin). Under usual conditions these drugs are used to increase
cardiac output in patients with mild to moderate degrees of
congestive heart failure. In this situation it is possible for the
physicians to prescribed a minimal dose of digitalis with
significant improvement in the patient's condition. However, in
cases of acute onset of congestive heart failure, as with
myocardial infarction, large or almost toxic doses of digitalis
preparations are often required. In this situation, it is usually
extremely difficult for the physicians to optimize drug dose while
avoiding toxic or lethal drug levels.
However, with the discovery of repetitive ventricular response
(RVR) to digitalis administration, it has been possible to develop
an automated system to control blood levels of digitalis
preparations.
In 1967, researchers reported that digitalization, while not
changing the diastolic excitability threshold for single responses,
would lower the threshold for RVR which followed the initial
ventricular contraction. See the following articles "Electrical
Stimulation and Digitalis Drugs: Repetitive Response in Diastole".
Proceedings of the Society For Experimental Biology and Medicine
1967, vol. 126,698- 701 and "Electrical Stimulation to Estimate the
Degree of Digitalization", The American Journal of Cardiology.
Aug., 1967, vol. 22, no. 2, pages 251-259.
A most important aspect of this phenomenon was the observed
widening of the zone of diastolic sensitivity as a function of the
degree of digitilization.
In almost all cases, about half the toxic dose of digitalis
preparations produced RVR with stimuli placed in about the midpoint
of the Q -- Q or somewhat earlier in the R -- R wave cardiac
interval. With increasing doses RVR could be obtained with stimuli
placed further and further into diastole. With toxicity approaching
100 percent, RVR could be elicited just before the P wave of the
next cardiac cycle.
Because of this consistent phase relationship between the degree of
toxicity and the percentage of diastole during which RVR could be
produced, it is now possible to precisely control digitalis
infusion for optimum dosage while avoiding serious side effects
(i.e., toxicity).
In accordance with this invention, controlled infusion of
digitalizing medications to patients, is achieved by detecting a
repetitive electrical event originating in the muscle of the heart,
generating an electrical stimulatory signal and applying it to the
heart a predetermined time interval after the onset of the
electrical event, and then detecting the response of the heart to
the electrical stimulatory signal to set the amount of medication
being administered to the patient depending on the indicated
toxicity of the patient.
An object of this invention is to provide a new and improved method
and device for administering digitalizing medications.
A further object of this invention is to provide a method and
apparatus for controlling the administration of digitalizing
preparations to patients.
The invention accordingly comprises the several steps and the
relation of one or more of such steps with respect to each of the
others, and the apparatus embodying features of construction,
combinations of elements and arrangements of parts which are
adapted to effect such steps, all as exemplified in the following
detailed description, and the scope of the invention will be
indicated in the claims.
For a fuller understanding of the nature and objects of the
invention, reference should be had to the following detailed
description taken in conjunction with the accompanying drawings, in
which:
FIG. 1 is an electrocardiogram illustrating the usual electrical
events (signals) generated by the heart of a patient,
FIG. 2 is an electrocardiogram illustrating the sequence of
electrical events (signals) showing the electrical stimulatory
signal applied to the heart and the (RVR) wave response to the
stimulatory signal,
FIG. 3 is a graph illustrating the percent toxicity of a patient as
an approximate function of the percent of the R -- R wave interval
during which the electrical stimulatory signal is applied to the
patient, which elicits an RVR response,
FIG. 4 is a block diagram illustrating the apparatus of the
invention, and
FIG. 5 is a more detailed diagram illustrating the apparatus of the
invention.
In FIG. 1, there is shown an electrocardiogram illustrating the
electrical signals associated with the contraction of the normal
heart. The P wave illustrates the atrial wave, the Q, R and S waves
illustrates the electrical signals associated with ventricular
contraction and the T wave illustrates the electrical signal
associated with ventricular repolarization.
In FIG. 2, there is shown an electrocardiogram illustrating the RVR
stimulatory wave form applied to the heart of a patient a
predetermined time interval after the initial contraction of the
heart along with RVR response wave of a patient having between
about 46 percent to about 100 percent of a toxic dose of a
digitalizing medication in the body.
FIG. 3 illustrates in graph form the relationship of percent
toxicity of a digitalized patient as an approximate percentage of
the R -- R or other appropriate interval in which a stimulatory
signal will cause an RVR wave to occur.
Reference should now be had to FIGS. 1 - 4. FIG. 4, in particular
illustrates in block diagram form the principals of the
invention.
To apply this invention to a patient, a catheter 10 containing an
open lumen, together with an electrode wire 11 is advanced through
an appropriate vein into the Superior Vena Cava. The electrode wire
11 is then further advanced into the right ventricular myocardium.
It should be understood that an electrode placed in the myocardium
is only one way to stimulate the heart muscle with electrical
signals. Electrical stimulating signals can also be applied by
external electrodes attached to the patient, via wires placed in
the esophagus or implanted in the patient as with a pacemaker.
An infusion pump 12 comprising an electrical motor driven syringe,
of the type commonly used and publicity available, is then
connected to the catheter. At 13 there is shown an EKG
(Electrocardiograph) device such as sold by Hewlett Packard and
many others for monitoring electrical signals from the heart.
The EKG provides electrical signals to a R wave filter 14 and an
RVR wave filter 15. These detected signals are then transmitted to
a control unit 16 (shown in greater detail in FIG. 5). The control
actuates the RVR wave stimulator 17 and also adjusts the infusion
rated base upon the position of the RVR envoking stimulus in the R
-- 6 R wave interval. The control unit 16 includes a delay control
which preferably seeks RVR signals with the RVR stimulus applied
after about 70 to 46 percent (can be varied between about 0 up to
100 percent) of the R -- R wave interval. Depending upon the
position of the RVR electrical stimulus in the R -- R interval
which elicits an RVR wave, the control unit either increases or
decreases the amount of medication being pumped into the patient by
the infusion pump 12.
Generally, the control unit will be set to maintain the infusion
rate such that about 70 percent of the toxic dose of digitalizing
medication is provided to the patient. Thus by detecting when
during the R -- R interval that an RVR stimulus produces an RVR
response wave the toxicity of the patient is determined (the
greater the toxicity of the patient, the later that an RVR stimulus
may be applied during the R -- R interval which will elicit an RVR
response). The apparatus in effect determines the toxicity of the
patient and then adjusts the infusion rate according to the percent
of the toxic dose desired to be maintained in the patient.
Reference should now be had to FIG. 5, which shows in logical block
diagram form the apparatus according to this invention. At 10, 11
and 13 are shown the catheter, electrode, and EKG monitor described
in FIG. 4. The infusion pump is shown at 12 and includes a motor 20
which drives a gear (not shown) which moves a rack 21 to force a
plunger 22 of the infusion pump forward at a controlled rate in
order to dispense medication to the patient.
The RVR stimulus is derived from stimulator 17. The stimulator 17
can be the usual type of physiological stimulator, as for example
the type made by Grass Instrument Company of Massachusetts. The
stimulator is set to preferably provide a 25 microjoule RVR
stimulatory wave signal to stimulate the heart. Obviously the
amount of energy provided to the heart will vary depending on the
patient and the manner in which the heart is stimulated. If the
heart is stimulated by external electrodes applied to the body of
the patient, higher energy levels are required.
A signal to trigger the stimulator 17 is derived in the following
manner; the R wave filter 14 (high pass filter>15 c.p.s.)
provides a signal to actuate Schmitt trigger 25. The signal from
trigger 25 resets an integrator 26 which is integrating a reference
voltage E reference. At the same time, the prior voltage at the
output of integrator 26 is gated into a gated sample voltage hold
circuit 27. The circuit 27 holds the voltage provided to its input
at its output terminal until a gating signal is provided. This type
of circuit 27 is available from the following companies; Hybrid
Systems of Massachusetts, Philbrick - Nexus of Massachusetts and
others. Thus there is provided at a voltage divider network 30 two
voltages, one a constant representing a voltage proportional to the
R -- R wave interval, inverted by inverter 31, and a second voltage
increasing during each R -- R wave interval. The inverted voltage
is provided to a variable plot 32, having a wiper arm 33 which is
driven by a DC motor 34 moving at a speed determined by voltage E
1, and the resistance 35. In this manner there is provided a
negative voltage at point 36 which is proportional to a percent of
the R -- R interval and an increasing voltage proportional to
elapsed time from the onset of the next R wave. The pot 32
functions so as to gradually reduce the negative voltage at point
36 and therefore to permit the RVR wave stimulator to provide RVR
stimuli successively earlier in the R -- R interval until a RVR
response is detected. Normally the pot 32 starts out so that a
voltage proportional to 70 percent of the R -- R interval is
provided.
When the two wave forms at point 36 cross over, a Schmitt trigger
37 is actuated which in turn triggers the RVR stimulator 17 to
produce an RVR stimulatory wave. The stimulator 17 preferably only
provides a stimulus every 10 seconds in order to give the heart
time to recuperate. This can be controlled by a clock 62 which
periodically closes a relay contact 63 through a solenoid. In the
alternative the output from trigger 37 can be periodically gated
using an AND gate controlled by a clock.
The output from Schmitt trigger is also fed to two coupled
monostable multivibrator circuits 39 and 40, the circuit 40 being
triggered by the delayed negative going portion of circuits 39 wave
form, to provide a window gating voltage at AND gate 41. The window
being such that AND gate 41 is permitted to open for a
predetermined interval about 46 to 70 percent of the R -- R
interval.
If we now assume that the patient is sufficiently toxic (over about
46 percent), we will now obtain an RVR response wave from filter 15
(low pass filter less than about 10 c.p.s.) which in turn triggers
a Schmitt trigger 16. Thus at the output of AND gate 41 we now have
a signal indicating that a RVR response is present.
The signal from gate 41 is used in part to set a bistable
multivibrator 42 closing relay contact 43 which places resistance
44 in parallel with resistance 35. Resistance R is selected such
that it is 10 times smaller than resistance 35. Thus motor 34
rapidly turns to reposition wiper 33 at its initial start position
as to again provide a negative voltage at point 36 proportional to
70 percent of the R -- R interval. As wiper 33 turns a protrusion
45 carried thereon closes a switch 46 to trigger circuit 47 to
reset bistable 42. In this manner the pot 32 is reset to once again
sample the toxicity of the patient.
In order to develop a voltage which is an indication of how far
into diastole an RVR stimulus has been applied which elicits an RVR
response, there is provided a bistable multivibrator 50 and a
resetable integrator 51 and a gated voltage hold circuit 52 of the
type previously described. Bistable 50 initially closes a contact
55 of a relay on receipt of an R signal from trigger 25. This
causes integrator 51 to integrate reference signal E ref 2 after
being reset by a signal from trigger 25. Bistable 50 is reset each
time by trigger 37 whenever a RVR stimulatory signal command is
given, which opens contact 55. Thus the voltage at the output of
integrator 51 is proportional to a voltage, indicating the time
between the presence of an R wave and the initiation of the RVR
stimulus. Assuming now that an RVR wave has been received from the
patient, gate 41 produces a signal to gate the voltage from
integrator 51 to the voltage hold circuit 52. The output from
voltage hold circuit 52 is then inverted and combined with a
reference signal E ref 3 indicative of the desired medication
(toxicity level) to be maintained in the patient. These signals are
combined in a differential amplifier circuit to generate an error
signal. The error signal is then combined in a servo loop shown at
60, with the amplifier being a long time constant integrator, to
develop a motor control signal in a manner well known to the art to
set the speed of motor 20.
The initial speed setting for the motor is provided by a reference
voltage E ref 4 on closure of contact 61.
In order to set the initial voltage for a voltage hold circuit 52
there is provided a voltage E 5 which through push button switch 65
sets an initial voltage in circuit 52. The voltage E 5 is
preferably selected so that it represents a voltage level that
could be expected if a patient was 50 percent toxic.
* * * * *